← Eichor
Condition: Graves Disease Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Graves Disease

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Modified Orbital Decompression in the Treatment of Moderate-to-severe Grave's Ophthalmopathy
NA · 1 location(s) · Sun Yat-sen University · NCT06588764Clinical Application of Al18F-NOTA-FAPI-04 PET/CT or PET/MRI Imaging in Malignant Tumor,Cardiovascular or Immune Disease
Phase 1/Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT07400224Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease
Phase 3 · 21 location(s) · Biohaven Therapeutics Ltd. · NCT07661056Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease
Phase 3 · 1 location(s) · Minghui Pharmaceutical (Hangzhou) Ltd · NCT07262476Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease
Phase N/A · 1 location(s) · Vastra Gotaland Region · NCT05678374Thyroidectomy for Graves' Disease or Amiodarone-induced Thyrotoxicosis
Phase N/A · 15 location(s) · Andrea Goldmann · NCT06963203Eye Tracking Study on Eye Movement Function and Visual Attention Patterns in Patients With Thyroid-Associated Ophthalmop
Phase N/A · 1 location(s) · Shanghai Changzheng Hospital · NCT07381413Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease
NA · 1 location(s) · Taipei Veterans General Hospital, Taiwan · NCT07400757Impact of Thyroid Hormones on Human Glucose and Energy Metabolism
NA · 1 location(s) · University of Ulm · NCT07410637Orbital Radiotherapy in Grave's Ophthalmopathy 1 Week vs 2 Weeks (OraGO-1 Trial)
Phase 3 · 1 location(s) · Janjira Petsuksiri · NCT06392906Course for Brain Fatigue After Graves' Disease Controlled Study
NA · 1 location(s) · Vastra Gotaland Region · NCT06134219Establishment of Multiparametric Prediction Models for Moderate to SevereThyroid Associated Ophthalmopathy
Phase N/A · 1 location(s) · Shanghai Changzheng Hospital · NCT06590220A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease
Phase 3 · 27 location(s) · Zai Lab (Shanghai) Co., Ltd. · NCT07211776Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Phase 2/Phase 3 · 2 location(s) · Sling Therapeutics, Inc. · NCT06112340An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease
Phase 2 · 8 location(s) · Amgen · NCT07438405Hydroxychloroquine in Mild Graves' Orbitopathy
Phase 4 · 2 location(s) · National Taiwan University Hospital · NCT05126147A Clinical Follow-up Study on Drug Therapy for Graves' Disease Patients in China
Phase N/A · 1 location(s) · First Hospital of China Medical University · NCT07040306Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter
Phase 3 · 1 location(s) · Jan Calissendorff · NCT04856488Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease
Phase N/A · 1 location(s) · Elazıg Fethi Sekin Sehir Hastanesi · NCT07480720Graves' Disease Remission Study: MycoMeth Combo
Phase 2/Phase 3 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06068179Personalized Treatment in Thyroid Disorders
NA · 1 location(s) · Johns Hopkins University · NCT03517579MHB018A Treatment in Patients With Active Thyroid Eye Disease
Phase 3 · 1 location(s) · Minghui Pharmaceutical (Hangzhou) Ltd · NCT06989918Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease
EARLY_Phase 1 · 1 location(s) · Shanghai Zhongshan Hospital · NCT07129642NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease
Phase 1 · 9 location(s) · Merida Biosciences · NCT07305818A Study of GensSci098 in Subjects With Graves' Disease
Phase 1 · 1 location(s) · Changchun GeneScience Pharmaceutical Co., Ltd. · NCT07286656The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Phase N/A · 1 location(s) · Walter Reed National Military Medical Center · NCT06275373A Study of IBI3031 in Participants With Thyroid Eye Disease
Phase 1 · 1 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT07622368The Impact of Person Centred Care (PCC) in Grave's Disease
NA · 1 location(s) · Vastra Gotaland Region · NCT06309316Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease
Phase 2 · 1 location(s) · Northwell Health · NCT07369063Bimatoprost as a Treatment for Graves' Orbitopathy
EARLY_Phase 1 · 1 location(s) · Johns Hopkins University · NCT03708627
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.